Start with its own history
Compare positive annual observations to understand how this company has been priced over time. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
ASX · NUZ.AXBiotechnologyUpdated Oct 22, 2026
Neurizon Therapeutics Limited P/E ratio
Current valuation, historical context, and peer comparisons.
Current P/E ratio
N/M
No meaningful positive P/E available.
Share price0.079
÷Earnings per share-0.0175
Price and EPS in quote currency. Calculation details
Zero or negative earnings do not produce a meaningful conventional P/E.
P/E over time
2017 – 2026
Not enough positive observations to chart this period. Available values are listed below.
Annual P/ESelected-period average N/M
3-year averageN/M0 positive annual observations
5-year averageN/M0 positive annual observations
10-year averageN/M0 positive annual observations
Peer median · TTMN/M0 peers with positive P/E
Historical P/E ratios
Annual period-end data · 25 observations
| Period end | P/E | Change |
|---|---|---|
| Jun 30, 2026 | N/M | N/M |
| Jun 30, 2025 | N/M | N/M |
| Jun 30, 2024 | N/M | N/M |
| Jun 30, 2023 | N/M | N/M |
| Jun 30, 2022 | N/M | N/M |
| Jun 30, 2021 | N/M | N/M |
| Jun 30, 2020 | N/M | N/M |
| Jun 30, 2019 | N/M | N/M |
View all 25 annual observations +
| Period end | P/E | Change |
|---|---|---|
| Jun 30, 2018 | N/M | N/M |
| Jun 30, 2017 | N/M | N/M |
| Jun 30, 2016 | N/M | N/M |
| Jun 30, 2015 | N/M | N/M |
| Jun 30, 2014 | N/M | N/M |
| Jun 30, 2013 | N/M | N/M |
| Jun 30, 2012 | N/M | N/M |
| Jun 30, 2011 | N/M | N/M |
| Jun 30, 2010 | N/M | N/M |
| Jun 30, 2009 | N/M | N/M |
| Jun 30, 2008 | N/M | N/M |
| Jun 30, 2007 | N/M | N/M |
| Jun 30, 2006 | N/M | N/M |
| Jun 30, 2005 | N/M | N/M |
| Jun 30, 2004 | N/M | N/M |
| Jun 30, 2003 | N/M | N/M |
| Jun 30, 2002 | N/M | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
How NUZ.AX compares
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
 NUZ.AX This stockNeurizon Therapeutics Limited | N/M |
 LV1.AXLive Verdure Ltd | N/M |
 KZA.AXKazia Therapeutics Limited | N/M |
 BNO.AXBionomics Limited | N/M |
 MDC.AXMedlab Clinical Limited | N/M |
 HXL.AXHexima Limited | N/M |
 RGS.AXRegeneus Ltd | N/M |
 ANP.AXAntisense Therapeutics Limited | N/M |
 EX1.AXExopharm Limited | N/M |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
What does NUZ.AX’s P/E tell you?
Compare like with like
Peer ratios add context to the company's own history. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
Check what drives earnings
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Take NUZ.AX into your spreadsheet
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore WisesheetsQuarterly P/E · latest quarterLQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data
=WISE("NUZ.AX", "PE Ratio", "LQ")Sources & calculation methodology
Current P/E
A conventional P/E is not meaningful when earnings are zero or negative. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Oct 22, 2026; this is not a real-time trading quote.
History & averages
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
Data definitions and limitations
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
NUZ.AX P/E ratio: common questions
The essentials behind the numbers.
Neurizon Therapeutics Limited does not currently have a meaningful positive P/E in the quote data. A zero or negative EPS makes the conventional P/E unsuitable for comparison.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.